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Aims Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially
cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combin-
ation of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in




Ceramides and PCs were analysed using liquid chromatography–mass spectrometry (LC-MS) in three studies:
WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention
with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen
Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best
prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was
highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95% confidence interval) per
standard deviation were 1.44 (1.28–1.63) in WECAC, 1.47 (1.34–1.61) in the LIPID trial, and 1.69 (1.31–2.17) in
KAROLA]. In addition, a combination of the risk score with high-sensitivity troponin T increased the HRs to
1.63 (1.44–1.85) and 2.04 (1.57–2.64) in WECAC and KAROLA cohorts, respectively. The C-statistics in
WECAC for the risk score combined with sex and age was 0.76 for CVD death. The ceramide-phospholipid risk
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score showed comparable and synergistic predictive performance with previously published CVD risk models
for secondary prevention.
...................................................................................................................................................................................................
Conclusion A simple ceramide- and phospholipid-based risk score can efficiently predict residual CVD event risk in patients
with coronary artery disease.
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Introduction
The number of patients with atherosclerotic coronary heart disease
(CHD) is increasing due to aging of the population and improved sur-
vival after CHD events. Coronary heart disease patients have been
considered a rather homogenous group in terms of their risk for fu-
ture cardiovascular (CV) events. However, Kaasenbrood et al.1 have
suggested that there is a substantial variation in the estimated 10-year
risk of recurrent vascular events in patients with vascular disease.
Hence considering all patients with vascular disease to be at similar
risk may not be entirely precise, and the proposed risk stratification
can be used to further optimize cardiovascular disease (CVD) pre-
vention in high-risk patients.1 This is an appealing proposition as tar-
geted prevention of recurrent CHD events may present an
opportunity for health economic gains.
In their study, Kaasenbrood et al.1 used the previously published
SMART risk score (Second Manifestations of Arterial disease) for es-
timation of the 10-year risk of myocardial infarction (MI), stroke, or
vascular death.2 The SMART risk score contains 14 clinical and la-
boratory variables allowing identification of vascular patients at high
risk for recurrent events. This model was tested in several cohorts
and, based on the findings, it was suggested that new risk estimation
algorithms could allow individualized patient care also for patients
with manifest CVD.1 Similarly the TIMI (Thrombolysis In Myocardial
Infarction) Risk Score for Secondary Prevention (TRS 2P) with 9-
point risk stratification tool predicts 3-year risk for cardiovascular
(CV) death, MI, and ischaemic stroke.3
We have previously demonstrated that distinct serum ceramide lip-
ids predict CV death in patients with stable CHD and acute coronary
syndrome, and are thus potential markers of residual risk.4 We were
keen to improve the performance of our test even further, in particular
as we had previously observed in LURIC5 and other unpublished studies
that phosphatidylcholines (PCs) could add predictive power. The PCs
were prominent candidates for test inclusion also because they could
be stably incorporated into our high throughput, quality controlled, clin-
ical ceramide assay.6 Ceramides and PCs come from different biosyn-
thetic pathways: ceramides are sphingolipids which contain a
sphingosine backbone attached to a fatty acid, while PCs have a choline
headgroup and two fatty acyl side chains.7 These two lipid classes also
differ in their distribution in lipoprotein particles.8 We performed a lipi-
domic analysis in three prospective CHD cohorts, which allowed us to
develop and validate a new ceramide- and phospholipid-based risk
stratification score. Furthermore, we also investigated whether a simple
combination of biomarkers would show synergy by combining the
ceramide–phospholipid score with the most predictive non-lipidomic
biomarker, high-sensitivity troponin-T (hsTnT).
Methods
Study cohorts
The data used in the current study were derived from three large
clinical studies: WECAC (The Western Norway Coronary Angiography
Cohort), LIPID (The Long-Term Intervention with Pravastatin in
Ischaemic Disease) trial, and KAROLA (Langzeiterfolge der
KARdiOLogischen Anschlussheilbehandlung). All studies were carried
out according to the Declaration of Helsinki and approved by the local
ethics committees, and are described in Supplementary material online,
Methods.
Analytical methods
The sample matrix was plasma for WECAC and LIPID trial, and serum for
KAROLA. For WECAC and KAROLA studies, the LC-MS/MS analyses
were performed on a hybrid triple quadrupole/linear ion trap mass spec-
trometer (QTRAP 5500, AB Sciex, Concord, Canada) equipped with an
ultra-high performance liquid chromatography (UHPLC) (Nexera-X2,
Shimadzu, Kyoto, Japan). Ceramide lipids were analysed with a validated
method,6 and the analysis of phospholipids was performed using a global
lipidomic screening platform,9 in addition to a targeted method for phos-
pholipids (PLs) referred herein as LCPL platform. Details of these methods
are described in Supplementary material online, Methods. The analysed
phospholipids and ions used in the current study are represented in
Supplementary material online, Table S1. Using synthesized lipid standards
it was confirmed that in the screening platform PC 36:6 corresponded to
PC 14:0/22:6 lipid and in the LCPL platform PC 16:0/22:5 contained an
omega3 docosapentanoic acid (DPA) side chain (Supplementary material
online, Figure S1). In the LIPID trial, the ceramides and phospholipids were
analysed as published recently.10 In the LIPID data, the phospholipids were
presented as summed composition species, and therefore, PC 38:5 was
used instead of PC 16:0/22:5, PC 36:6 instead of PC 14:0/22:6, and PC 32:0
instead of PC 16:0/16:0 in the analyses.
Statistical methods
All statistical calculations were performed using R software. The analyses
were performed for two outcomes: CV death, and a composite CV event
endpoint, which included CV death, MI, and stroke. For development of
the new risk score, we utilized the four established ceramide molecules
and ceramide ratios, which have been shown to predict CV death,4 as
well as those 12 phospholipids (Supplementary material online, Table S1)
that significantly predicted CV events in the WECAC study. All possible
lipid-to-lipid ratios for these molecules were calculated, and from these
ratios and individual lipid molecules four variables were selected for
the risk score in a stepwise manner (Supplementary material online,
Figure S2). Based on these variables, a 0–12 point risk scoring system was
developed by giving points based on the population quartiles for the vari-
ables (Supplementary material online, Table S2), and based on the scores
the individuals were divided into four risk categories (Supplementary































































































material online, Table S3). Other statistical methods are described in
detail in Supplementary material online, Methods.
Results
Development and performance of a new
prognostic lipid score
As phospholipids have shown prognostic value for CV events,10 we
investigated whether a ceramide test score (CERT1) could be
improved by adding certain PCs. Key drivers of our selection process
were analytical stability, ability to incorporate into the existing assay6
and statistical robustness across several clinical cohorts. The new
ceramide test score, named CERT2, was developed in the WECAC
study and validated in the LIPID and KAROLA studies (Table 1), by
selecting the test components in a stepwise manner (Supplementary
material online, Figure S2, Supplementary material online, Table S4).
The original CERT1 score consisted of three single ceramides and
three ceramide/ceramide ratios, whereas the CERT2 score had one
ceramide/ceramide ratio, two ceramide/PC ratios and a single PC. In
general, the ceramide-PC ratio components of the CERT2 test
showed higher HRs than the previously published ceramide–ceram-
ide ratios,4 across all three studies (Supplementary material online,
Table S5).
The performance of the CERT2 score, in addition to other CV bio-
markers, was evaluated for CV death (Table 2) and CV composite
events (CV death, MI, and stroke; Supplementary material online,
Table S6). For CV death, the HRs (95% confidence interval) per
standard deviation (SD) for CERT2 were 1.50 (1.35–1.68) in
WECAC, 1.51 (1.38–1.65) in the LIPID trial, and 1.62 (1.32–2.00) in
KAROLA. For all the investigated biomarkers, the HRs for CV events
were lower than for CV death [for CERT2 the HRs per SD were
1.36 (1.25–1.48) in WECAC; 1.28 (1.21–1.37) in the LIPID trial; and
1.18 (1.03–1.36) in KAROLA)] (Supplementary material online, Table
S6). Adjustments with traditional CV risk factors and biomarkers did
not materially affect the results (Table 2, Supplementary material on-
line, Table S6). In WECAC, for CERT2 the HR for non-CV deaths
was lower than for CV deaths, and the score predicted MIs and
strokes also when not combined into the CV event composite end-
point (Supplementary material online, Table S7).
Combination of CERT2 with other
biomarkers
We also wanted to test the performance of CERT2 with other bio-
markers that were available for each study. We developed an add-
itional score that combined both CERT2 and hsTnT, as in WECAC
the performance of CERT2 and hsTnT appeared to be better than
that of other evaluated biomarkers (Table 2), and since we had valid-
ation data available in KAROLA. This demonstrated added value over
single biomarkers and CERT2-TnT score showed higher HRs than
CERT2 or hsTnT alone [for CV death HRs per SD in WECAC 1.79
(1.59–2.00) and KAROLA 1.92 (1.55–2.37)] (Table 2 and
Supplementary material online, Table S6). In KAROLA, also another
strong published secondary prevention CVD biomarker, NT-
proBNP,11 was measured and combination of CERT2 with this bio-
marker showed comparable results as combination with hsTnT
(Supplementary material online, Table S8). Thus, also other
biomarkers may show synergy with CERT2, but for further analyses
we focused on CERT2-TnT since we had validation data only for this
combination at present.
Performance of biomarkers in subgroups
Statin treatment might affect the performance of CVD biomarkers,
but in the LIPID trial cox regression models the CERT2-treatment
arm interaction did not show significant interaction (P = 0.13 for CV
death and P = 0.14 for CV events). Furthermore, we investigated the
performance of the markers in a statin free population, i.e. in the
LIPID trial placebo arm. This analysis validated CERT2 score results
obtained in the WECAC and KAROLA cohorts, and showed that
conventional lipid markers show weaker prognostic value for CV
death and CV events (Supplementary material online, Table S9).
Furthermore, in WECAC and LIPID trial, we investigated the per-
formance of the biomarkers separately in subjects with and without
diabetes mellitus. It appeared that the cardiovascular risk prediction
in subjects with diabetes mellitus is particularly challenging, as the
only biomarkers showing value in this patient population were
CERT2, hsTnT, or their combination (Supplementary material online,
Table S10).
Stratification of patients into risk groups
For clinical use, we divided the ceramide scores (CERT2 and CERT2-
TnT) into four risk groups ranging from low- to high risk
(Supplementary material online, Table S3), and in all three studies the
risk for CV death and CV events systematically increased along with
increasing score and risk group (Table 3, Supplementary material on-
line, Table S11). For CV death, a 3.5- to 5.4-fold risk increase was
observed in different cohorts between the lowest- and highest-risk
groups for CERT2, whereas the difference for the CV events was
more modest. Noteworthy, for the CERT2-TnT score a more than
10-fold increased risk was observed when comparing low- and high-
risk groups. The risk increase appeared consistent along with increas-
ing score. The largest risk increase was observed in patients who
scored more than 6 points out of 12 maximum points (Figure 1). The
same result was achieved in the statin free population
(Supplementary material online, Figure S3) of the LIPID trial. Finally,
Kaplan–Meier curves demonstrated the strong association of CERT2
and CERT2-TnT with CV death and CV events (Figure 2). For com-
parison, Kaplan–Meier curves for LDL-cholesterol (LDL-C) are
shown in Supplementary material online, Figure S4.
CERT2 improves existing risk estimation
models
Among WECAC patients, CERT2 combined with sex and age
reached C-statistics of 0.76 and CERT2-TnT of 0.78 in relation to CV
deaths (Table 4). For CV composite events, the C-statistics values
were lower, 0.65 for CERT2 and 0.66 for CERT2-TnT, when com-
bined with sex and age. However, these values were comparable
with the SMART score C-statistics (0.64) predicting 5-year risk for
CV events, and the TIMI score (0.64) predicting 3-year risk for CV
events. As the CERT2 was developed based on the WECAC study,
we also investigated the performance of the SMART and TIMI scores
when the coefficients of the variables were based on the same co-
hort. In this case, the SMART variables showed higher performance













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(0.67) than CERT2 with sex and age. However, in all cases, of prede-
fined and fitted scores based on WECAC, addition of CERT2
increased the C-statistics and also showed significant increase both in
categorical and continuous net reclassification index (NRI). For in-
stance, CERT2-TnT on top of the SMART score showed an overall
NRI of 0.072 (95% CI 0.030–0.113) and a continuous NRI of 0.289
(0.187–0.392). Values for the addition of CERT2-TnT on top of
the TIMI score were 0.123 (0.065–0.181) and 0.236 (0.119–0.354),
respectively. In both cases, the categorical NRI improved more for
events than for non-events, whereas the opposite was true for the
continuous NRI models (Table 4). CERT2 improved C-statistics also
on top of other conventional risk factors and biomarkers in all three
cohorts, as shown in Supplementary material online, Table S12.
Discussion
Our previously developed ceramide risk score (CERT) and its com-
ponents have shown superior performance in comparison with trad-
itional CV risk markers. In this study, we developed a novel and even
more powerful ceramide- and phospholipid-based risk score for
CHD, called CERT2, by combining three PC molecules with the pre-
viously published four ceramide lipids (Take home figure).4,12 Our
results showed that the molecular lipid-based risk estimation tool
had improved performance metrics and can be thus used to reliably
stratify CHD patients for their risk of CV events, especially CV death.
The data exposed a large variability in residual risk among the study
patients and the CERT2 score demonstrated an excellent and poten-
tially clinically relevant prognostic value. We also showed that add-
itionally improved prognostics can be achieved by combining CERT2
with other biomarkers, such as hsTnT.
The strengths of our study include the derivation/validation ap-
proach applying three independent CHD cohorts from Europe
(WECAC, KAROLA) and Australia (LIPID), with a long-term follow-
up. Furthermore, one of the study cohorts (LIPID) included a
placebo-controlled statin trial, which allows assessment of risk associ-
ations also in a population without interfering lipid-lowering treat-
ments. A limitation of the study was that the PCs, and partly
ceramides, were analysed with a slightly different analytical method-
ology in all three cohorts, which did not allow us to compare the cali-
bration of the score across the cohorts. Notably, however, within
different cohorts the results replicated well despite these different
methodologies. Thus, it appeared that the lipids described in this
study were robust both statistically and analytically, although a fully
validated mass-spectrometric laboratory method will be needed for
the clinical application of CERT2.
One of the main challenges in CV risk estimation is often the mod-
est discriminatory power of the tests and models. However, in this
study a simple biomarker score (CERT2 or CERT2-TnT) together
with the information on age and sex reached a C-statistics of 0.76,
which can be considered fairly acceptable for multifactorial diseases
like CHD. A certain level of residual risk always remains in CHD, and
thus, the value of prognostic estimation is in the accurate identifica-
tion of patients that exceed an acceptable risk level while on their
current treatment. CERT2 improved C-statistics when added on top
of the two recent risk scores, the SMART and TIMI risk scores. Also













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was added on top of the SMART or TIMI scores, even if the coeffi-
cients of these variables were fitted for our current study. Overall,
the CERT2 score appeared to provide at least as accurate informa-
tion as the more comprehensive clinical scores suggesting that a sim-
ple laboratory test-based risk estimation could become a practical
tool for daily clinical use. The wider adoption of various clinical scores
into practice is hampered by the large number of needed variables
that may not be easily available, in addition to the time consuming
data entry required for these computerized algorithms. Thus, a single
blood-based prognostic analysis would be expected to be more prac-
tical and also cost-efficient in daily clinical use. It is also worth noting
that the most critical biomarker in the CV field, LDL-C, showed a
very weak association in predicting outcomes. While LDL-C plays a
central role in the aetiology of atherosclerosis, its value as a biomark-
er in secondary prevention appears limited across all studies. LDL-C
concentration change is useful in monitoring lipid-lowering treatment
response and compliance, while CERT2 may provide a more inform-
ative read-out of the patient’s residual risk for secondary events. A
significant finding of this study was also the lack of predictive power
of traditional blood biomarkers in patients with diabetes mellitus, and
particular attention should be paid to what blood chemistry is used
to guide their risk assessment.
According to current guidelines, subjects with diagnosed CHD al-
ways belong to a very high-risk population.13 However, in light of the
present and recently published data1 it appears that the risk is highly
variable in this patient group. Importantly, our data show that the ma-
jority of CHD patients may have a relatively low long-term risk, <5%
CV death risk in ten years. On the other hand, our data suggest that,
indeed, 10–20% of all CHD patients do have an extremely high risk,
i.e. 10-year risk in the range of 15–20% for CV death. CERT2 may
thus add a new personalized treatment opportunity to the current
practice as it appears that certain patients are well off with the cur-
rent therapy, while in the others significant residual risk remains that
should be addressed more aggressively. These more effective means
are likely to include higher statin and other lipid-lowering medication
doses, anti-thrombotic treatments, well maintained blood pressure
targets, and intense lifestyle coaching to improve adherence to given
therapies. As an example, in the PREDIMED trial, participants with
high-ceramide concentrations were shown to benefit from
Mediterranean diet,14 and in another study, PCSK9 inhibition was
shown to benefit especially those subjects at high CV risk.15 In the fu-
ture, biomarker guided risk stratification may be part of a more cost-
efficient personalized treatment of CHD.
Ceramides are known to affect several CHD-related processes,
including LDL aggregation and uptake, endothelial dysfunction and
multiple inflammatory processes.4 Interestingly, two out of three
phospholipids selected in CERT2 contained polyunsaturated fatty
acids (PUFAs). Both DPA (22:5) and docosahexaenoic acid (22:6) be-
long to the omega3 (n - 3) fatty acid series, which may have several
positive CHD-related effects, such as anti-thrombotic and anti-
inflammatory effects, in addition to influencing overall lipid metabol-
ism, heart rate, blood pressure, and endothelial function.16 However,
dietary and n - 3 fatty acid supplementation trials have shown dis-
cordant results in the prevention of CV events,17 which is exemplified
also by two recent large trials: while n - 3 fatty acids were not
shown to affect statistically significantly major cardiovascular events










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































investigated in the REDUCE-IT showed a 25% relative reduction of
cardiovascular events.19 An interesting area for further studies is to
test whether CERT2 could identify those subjects that will benefit
from n - 3 fatty acid supplementation.
In conclusion, CERT2 score offers an easy to use tool for residual
risk estimation in CHD. This validated risk stratification tool may be
used to further improve development of personalized management
of CHD, which should be tested in future prospective studies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Figure 1 Risk curves for CERT2 and CERT2-TnT scores in (A) WECAC, (B) KAROLA, and (C) LIPID studies. The risks are calculated for 10 years
in KAROLA and WECAC cardiovascular death, and 6 years in LIPID trial and WECAC cardiovascular events. In Y-axes, the annual risk rates are
shown in parentheses.
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Figure 2 A Kaplan–Meier curves for (A) CERT2 and CERT2-TnT scores in WECAC and (B) CERT2 in the placebo and pravastatin treatment arms
in the LIPID trial.
............................................................. .............................................................
....................................................................................................................................................................................................................
Table 4 C-statistics together with categorical and continuous NRI values for selected variables in the WECAC study
Categorical NRId Continuous NRI












Sex þ age CV death 0.719
Sex þ age þ CERT2 CV death 0.755 0.158 (0.040–0.276) 12.3 3.5 0.316 (0.137–0.495) 11.5 20.1
Sex þ age þ CERT2-TnT CV death 0.776 0.196 (0.069–0.322) 14.2 5.4 0.581 (0.408–0.754) 31.7 26.4
Sex þ age CV event 0.620
Sex þ age þ CERT2 CV event 0.645 0.049 (0.005–0.094) 2.2 2.7 0.276 (0.178–0.374) 12.5 15.1
Sex þ age þ CERT2-TnT CV event 0.660 0.092 (0.041–0.142) 4.1 5.1 0.348 (0.250–0.447) 16.4 18.4
SMART score CV event 0.644
SMART score þ CERT2 CV event 0.652 0.047 (0.011–0.083) 7.3 –2.7 0.146 (0.044–0.248) 4.5 10.1
SMART score þ CERT2-TnT CV event 0.661 0.072 (0.030–0.113) 11.4 –4.2 0.289 (0.187–0.392) 13.0 15.9
SMART variablesa CV event 0.666
SMART variables þ CERT2 CV event 0.675 0.053 (0.015–0.090) 2.5 2.8 0.172 (0.074–0.271) 7.7 9.6
SMART variables þ CERT2-TnT CV event 0.685 0.090 (0.047–0.132) 5.1 3.9 0.269 (0.170–0.368) 13.4 13.5
TIMI score CV event 0.644
TIMI score þ CERT2 CV event 0.658 0.069 (0.023–0.115) 10.1 –3.1 0.140 (0.023–0.256) 0.6 13.3
TIMI score þ CERT2-TnT CV event 0.672 0.123 (0.065–0.181) 11.3 1.0 0.236 (0.119–0.354) 6.3 17.3
TIMI variablesb CV event 0.659
TIMI variables þ CERT2 CV event 0.669 0.061 (0.021–0.102) 2.3 3.9 0.152 (0.036–0.268) 9.7 5.5
TIMI variables þ CERT2-TnT CV event 0.679 0.081 (0.026–0.136) 1.7 6.4 0.238 (0.121–0.355) 10.3 13.5
aSMART score variables: age, age2, sex, current smoking, systolic blood pressure, diabetes mellitus, prior MI, prior stroke, PAD, years since first diagnosis of vascular disease,
HDL-C, TC, GFR, GFR2, and hsCRP.
bTIMI score variables: age, current smoking, hypertension, diabetes mellitus, prior CABG, prior stroke, PAD, heart failure, and GFR.
cFor TIMI score and variables, the calculations were performed for 3 years. All other results are shown for 5-year risk.
dThe categorical NRI cut-offs were 2.5% and 7.5% for 5-year risk of CV death, 5% and 15% for 5-year risk of CV events, and 5% and 10% for 3-year risk of CV events.
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